AZGP1:癌症中的蛋白质组学生物标志物
本综述基于免疫测定与质谱研究,评估AZGP1作为血清生物标志物在多种恶性肿瘤中的分析性能与临床效用。ELISA与化学发光免疫测定对早期结直肠癌和前列腺癌检测的曲线下面积为0.78-0.89,常优于前列腺特异性抗原和癌胚抗原水平。质谱研究鉴定出AZGP1蛋白质变体,其丰度与肿瘤负荷和进展相关。
要点
- ELISA与化学发光免疫测定检测早期结直肠癌和前列腺癌的AUC为0.78-0.89。
- 血清AZGP1升高独立预测结直肠癌、肺癌和乳腺癌较差的总生存和无病生存。
- 需统一分析前和分析方案,并开发参考标准、开展大型前瞻性试验。
核心结论
- 血清AZGP1有潜力成为改善早期检测、预后分层和精准肿瘤学的可靠微创生物标志物。
研究设计与样本
- 综述,基于免疫测定和质谱研究评估AZGP1的分析性能与临床效用。
主要发现
- ELISA和化学发光免疫测定对早期结直肠癌和前列腺癌检测的曲线下面积为0.78-0.89,常超过前列腺特异性抗原和癌胚抗原水平。
- 质谱研究鉴定出AZGP1蛋白质变体,其丰度与肿瘤负荷和进展相关。
- 多变量临床分析证实血清AZGP1水平升高独立预测结直肠癌、肺癌和乳腺癌较差的总生存和无病生存。
- 临床前模型显示AZGP1参与脂质动员、上皮-间质转化及肿瘤-基质和免疫相互作用调节。
关键数值与推荐
- ELISA和化学发光免疫测定检测早期结直肠癌和前列腺癌的AUC为0.78-0.89。
临床怎么用
- 血清AZGP1有望用于癌症早期检测、预后分层和精准肿瘤学决策。
局限性
- 需统一分析前和分析方案,并开发参考标准、开展大型前瞻性试验及利用人工智能发现联合蛋白质组特征。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Alpha-2-glycoprotein 1, zinc-binding (AZGP1), functions as a serum AZGP1 biomarker with applications in cancer detection, prognosis, and therapeutic monitoring. This review evaluates AZGP1's analytical performance and clinical utility in multiple malignancies based on immunoassay and mass spectrometry studies. ELISA and chemiluminescent immunoassays yield area-under-curve values of 0.78-0.89 for early colorectal and prostate cancer detection, often surpassing prostate-specific and carcinoembryonic antigens levels. Mass spectrometry studies have identified AZGP1 proteoforms, the abundance of which correlates with tumor burden and progression. Multivariate clinical analyses confirmed that elevated serum AZGP1 levels independently predict poorer overall and disease-free survival in colorectal, lung, and breast cancers. Simultaneously, preclinical models have demonstrated the role of AZGP1 in lipid mobilization, epithelial-mesenchymal transition, and modulation of tumor-stromal and immune interactions. We highlight the integration of mechanistic insights with proteoform-specific data and the need to harmonize preanalytical and analytical protocols. We propose a plan that includes the development of reference standards, conducting large prospective trials within biobank networks, and using artificial intelligence to discover combined proteomic signatures of the disease. These efforts aim to establish serum AZGP1 as a reliable, minimally invasive biomarker that improves early detection, prognostic stratification, and informs precision oncology.
引用
- Pandey SN, Afzal M, Ali H, et al. AZGP1: A proteomic biomarker in cancer. Clin Chim Acta. 2025. PMID: 40659174. doi:10.1016/j.cca.2025.120481
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。